Paloma Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Paloma Partners’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,800	Closed	-$478K	–	2406
2017 Q3	$478K	Buy	+5,800	New	+$460K	0.01%	1548

Other funds holding CLVS

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Paloma Partners's CLVS Position: Q1 2022 in Review

Paloma Partners sold out of Clovis Oncology, Inc. (CLVS) in Q1 2022, closing a stake of 20,336 shares — an estimated $55K sold.

Paloma Partners first reported a position in CLVS in Q1 2014 and held it in 4 quarters. The position peaked at $1.73M in Q1 2014. 153 funds tracked by Wall St. Rank hold CLVS as of Q1 2022.

Paloma Partners reported no remaining Clovis Oncology, Inc. position as of Q1 2022 after selling out during the quarter.
Paloma Partners sold 20,336 Clovis Oncology, Inc. shares in Q1 2022, an estimated $55K.
Paloma Partners first reported a position in Clovis Oncology, Inc. in Q1 2014 and held it in 4 quarters.
Paloma Partners's Clovis Oncology, Inc. position peaked at $1.73M in Q1 2014.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2022.

Based on Paloma Partners's 13F filing for Q1 2022, filed 16 May 2022.